Takeda Chemical Industries, Inc.

National Cancer Center

Children's Medical Center Corporation

Koichi Igarashi

Tsutomu Kurokawa

Reiko Sasada

Makoto Iwane

Masaaki Terada

Masaharu Senoo

Tadashi Yamamoto

Moses J Folkman

Koji Yoshimura

Ryuji M Marumoto

Yuen Shing

Yasushi Nagata

Kaori Ishimaru

Tomoko Fujii

Kumao Toyoshima

Ryuya Horiuchi

Kiyoshi Yamauchi

Tetsuya Saito

Osamu Nishimura

Susumu Iwasa

Takashi Ito

Koichi Kondo

Yoshio Kozai

Yuzo Ichimori

Hitoshi Mori

Sumie Yoshitomi

Yoshihiko Kaisho

Teruhiko Yoshida

Hiromi Sakamoto

Yoko Tanaka

Masaharu Sendo

Yasuyuki Kajiwara

Masayuki Kobayashi

Mitsuyo Kondo

Toshifumi Mori

The betacellulin mutein or its salt of the present invention is useful for better therapeutic drug for diabetes. Since they have intact BTC activity and reduced EGF activity, and no antigenicity-related problems.

Betacellulin modification

The present invention provides a polypeptide represented by the following amino acid sequence:

Nucleic acids encoding HST 2 muteins

A recombinant non-glycosylated mammalian growth factor (BTC-GF) stimulates proliferation of human smooth muscle cells. Especially, the amino acid sequence of the protein deduced from the nucleotide sequence coding for human BTC-GF is as that comprising the amino acids No. 1 to No. 147 of FIG. 10 (SEQ ID NO:18) or the amino acids No. 1 to 80 of FIG. 10, (SEQ ID NO:18) and the amino acid sequence of the protein deduced from the nucleotide sequence coding for mouse BTC-GF is as that comprising the amino acids No. 1 to No. 146 of FIG. 9 (SEQ ID NO:17).

Smooth muscle mitogen and isolated DNA coding therefor

A monoclonal antibody is produced from a cloned hybridoma, and the monoclonal antibody combines specifically with basic fibroblast growth factor (bFGF). Therefore, the monoclonal antibody can be advantageously used for assay reagents on bFGF or for purification of bFGF.

Monoclonal antibody, hybridoma, their production and use thereof

A recombinant non-glycosylated mammalian growth factor (BTC-GF) stimulates proliferation of human smooth muscle cells. Especially, the amino acid sequence of the protein deduced from the nucleotide sequence coding for human BTC-GF is as that comprising the amino acids No. 1 to No. 147 of FIG. 10 (SEQ ID NO:5) or the amino acids No. 1 to 80 of FIG. 10 (SEQ ID NO:18), and the amino acid sequence of the protein deduced from the nucleotide sequence coding for mouse BTC-GF is as that comprising the amino acids No. 1 to No. 146 of FIG. 9 (SEQ ID NO:17).

Smooth muscle mitogen peptides and DNA coding therefor

Protein disulfide isomerase, which catalyzes the exchange reaction between sulfhydryl and disulfide in a protein for formation of the most stable natural type disulfide bonds, is useful for formation of natural type disulfide bonds in a protein which is produced in a prokaryotic cell.

Protein disulfide isomerase and method of using

A mutein of basic fibroblast growth factors (bFGF) possesses fibroblast growth promoting activity, growth stimulating activity of capillary endothelial cells and angiogenic activity, has high stability and is low toxicity. And therefore, the present mutein is advantageously used as a healing accelerator for burns etc., a therapeutic drug for thrombosis etc., and a cell cultivation promoter.

Basic fibroblast growth factor (bFGF) muteins

Protein disulfide-isomerase and production thereof

The present invention provides a polypeptide represented by the following amino acid sequence: ##STR1## wherein n is 0 or 1 and X represents Pro Ala Gly Thr Arg Ala Asn Asn Thr Leu Leu Asp Ser Arg Gly Trp Gly Thr Leu Leu Ser Arg Ser Arg Ala Gly or a fragment thereof (n=0: SEQ ID NO:1, n=1: SEQ ID NO:2), a recombinant DNA coding for the polypeptide, a vector containing the recombinant DNA, the preparation of a transformant carrying the vector, and the production of the polypeptide with the transformant. The use of this peptide in pharmaceutical compositions is also provided.

Hst-2 muteins, pharmaceutical compositions and kits comprising same, and

A deletion type mutein of heparin-binding secretory transforming factor (hst-1) possesses excellent cell growth promoting activity and is stable. The present mutein can therefore be used as a therapeutic medicine such as a healing promoter for burns, wounds, surgical injuries etc.

Deletion muteins of hst-1

A transformant, which harbors a recombinant vector containing a DNA which codes for human nerve growth factor 2 and a DNA which codes for the pro-region of a nerve growth factor at 5'-terminal of said DNA, produces human nerve factor 2 in stable and large amount in a culture medium.

Method for producing human nerve growth factor 2

A method of increasing platelets in mammals which comprises administering to mammals an effective amount of a heparin-binding secretory transforming factor 1 protein (hst-1) having an N-terminal deletion of 27 amino acids.

N-terminally truncated hst-1 is a platelet-increasing factor

Hybridomas and monoclonal antibodies which specifically bind human basic

Disclosed are (1) a mutein of a fibroblast growth factor (FGF), the DNA having introduced therein at least one nucleotide sequence coding for a glycosylation site, (2) a DNA coding for the mutein of (1), (3) a vector containing the DNA of (2), (4) a transformant transformed with the vector of (3), and (5) a process for producing the mutein which comprises cultivating in a culture medium the transformant of a yeast or animal cell transformed with a vector of (3), and producing and accumulating the mutein of (1) in the culture medium, whereby the FGF mutein into which at least one glycosylation site has been introduced is improved in productivity, stability and activities, and advantageously used as medicine.

DNA encoding glycosylated FGF and production thereof

Growing community of inventors

Kyoto, Japan

Koichi Igarashi